Open an account

Genprex

GNPX · NASDAQ

$2.13+$0.07 (+3.40%)TodayMarket closed ·
Prev close $2.06

About GNPX

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 13 full-time employees. The company went IPO on 2018-03-29. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

Employees
13
Headquarters
Austin, Texas
Listed
Mar 29, 2018
Sector
Health Care
Industry
Biotechnology
Website
genprex.com

GNPX key statistics

Market cap
1.75M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
295.15K
Volume
234.31K
Open price
$2.07
High today
$2.18
Low today
$2.03
52 Week high
$386.10
52 Week low
$2.06

Genprex (GNPX) at a glance

Genprex (GNPX) last traded at $2.13, with a market cap of 1.75M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.03 and $2.18. The current price is 4.9% above the day's low and 2.3% below its high.

Volume so far is 234.31K shares, below the average of 295.15K shares a day.

Over the past year Genprex has ranged from $2.06 to $386.10, and now sits 0% of the way up that range.

Genprex met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q1 FY26 it reported -$0.64 per share against an estimate of $0.00.

GNPX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 25.5% on average.

  1. Q3 FY23: reported -$5,720.00 per share against an estimate of -$4,936.80
  2. Q4 FY23: reported -$4,356.00 per share against an estimate of -$4,409.46
  3. Q1 FY24: reported -$4,059.00 per share against an estimate of -$2,849.88
  4. Q2 FY24: reported -$3,300.00 per share against an estimate of -$2,580.60
  5. Q3 FY24: reported -$1,353.00 per share against an estimate of -$2,165.46
  6. Q4 FY24: reported -$1,265.00 per share against an estimate of -$437.58
  7. Q1 FY25: reported -$286.00 per share against an estimate of -$460.02
  8. Q1 FY26: reported -$0.64 per share against an estimate of $0.00

GNPX news

  • Press releasePRNewswire

    Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releasePRNewswire

    Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releasePRNewswire

    Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

  • Press releasePRNewswire

    Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

  • Press releasePRNewswire

    Genprex to Participate at BIO International Convention 2026

  • Press releasePRNewswire

    Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

  • Press releasePRNewswire

    Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Similar companies

Companies in the same industry as Genprex

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.